Supplemental Postoperative Bupivacaine

Phase 2Small molecule

Supplemental Postoperative Bupivacaine is one of 3 small molecule programs targeting Endodontic Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endodontic TreatmentRecruiting

Endodontic TreatmentPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Endodontic Treatment

#DrugCompanyPhaseTrials

Trypsin-Chymotrypsin

DDow University of Health Sciences

Phase 3

1 2

Supplemental Postoperative Bupivacaine

NNew York University

Phase 2

1 3

Platelet Rich Fibrin

GGovernment Dental College and Research Institute, Bangalore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endodontic Treatment1 trial

Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment

Recruiting·NNew York University·Phase 2·NCT06655454·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Supplemental Postoperative Bupivacaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Supplemental Postoperative Bupivacaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Supplemental Postoperative Bupivacaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNew York University

Supplemental Postoperative Bupivacaine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endodontic Treatment1 trial

References

Drug Info

Quick Facts

Related News